Sanofi-aventis Canada Inc., in consultation with Health Canada, is
recalling all lots of Allerject (0.15 mg/0.15mL and 0.3 mg/0.3 mL strength epinephrine auto-injectors) from the Canadian market. A similar recall is taking place in the United States, where it’s sold as Auvi-Q.
This recall is due to issues that may potentially affect the delivery of the required amount of the drug, epinephrine. Allerject is used as an emergency treatment by patients who are at risk and/or have a history of serious allergic reactions (anaphylaxis).
In light of the need to manage supply associated with this recall, we are asking customers and pharmacists to limit the replacement of Allerject to one unit or the appropriate number of units as instructed by your healthcare professional until full alternative stock is available.
Adults and children who use Allerject (0.15 mg / 0.15 mL and 0.3 mg/0.3 mL auto-injector).
Health Canada is monitoring the company’s recall and will inform Canadians if any new information arises.
How to report side effects to health products to Health Canada:
-
Call toll-free at 1-866-234-2345
-
Visit MedEffect Canada's web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
Stay connected with Health Canada and receive the latest advisories and product recalls using
social media tools.
Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.
More information is also available from sanofi-aventis Canada Inc. by calling the Allerject call centre at 1-855-405-4321 or on the sanofi-aventis Canada Inc. website (www.sanofi.ca).
Health Canada
(613) 957-2983
(613) 957-2991
1-866 225-0709